Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0006-8993(78)90915-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [F]FDG PET Neuroimaging.
Int J Mol Sci
November 2024
Unidad de Cartografía Cerebral, Instituto Pluridisciplinar, Universidad Complutense de Madrid, 28040 Madrid, Spain.
4-aminopyridine (4-AP) is a non-selective blocker of voltage-dependent K channels used to improve walking in multiple sclerosis patients, and it may be useful in the treatment of cerebellar diseases. In animal models, 4-AP is used as a convulsant agent. When administered intrahippocampally, 4-AP induces acute local glucose hypermetabolism and significant brain damage, while i.
View Article and Find Full Text PDFFrontal neurodegeneration associated with Frontal Assessment Battery in early Alzheimer's disease.
J Neurol Sci
December 2024
Department of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Background: The Frontal Assessment Battery (FAB) is widely used to assess executive dysfunction in patients with amnestic mild cognitive impairments due to Alzheimer's disease (aMCI-AD), but its neurobiological meaning is unclear. To elucidate this, we examined the relationship between the FAB score and three key imaging biomarkers: gray matter volume, amyloid-beta (Aβ) deposition, and glucose metabolism.
Methods: Twenty Aβ- and tau-positive aMCI-AD patients and age-matched controls underwent structural magnetic resonance imaging and positron emission tomography with [C]PiB and [F]FDG.
Mapping of the Glucose Metabolism Heterogeneity in Atherosclerosis: Correlation With 2-Deoxyglucose Uptake.
Mol Imaging
November 2024
Departments of Radiology, Division of Cardiothoracic Imaging, University of Pittsburgh, Pittsburgh, PA, USA.
Objective: 2-Deoxy-2-[F]fluoro-D-glucose ([F]FDG) is widely used for noninvasive imaging of atherosclerosis. However, knowledge about metabolic processes underlying [F]FDG uptake is mostly derived from cell culture studies, which cannot recapitulate the complexities of the plaque microenvironment. Here, we sought to address this gap by mapping of the activity of selected major dehydrogenases involved in glucose metabolism in atherosclerotic plaques.
View Article and Find Full Text PDFBrain imaging and machine learning reveal uncoupled functional network for contextual threat memory in long sepsis.
Sci Rep
November 2024
Laboratory of Immune and Neural Networks, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.
Positron emission tomography (PET) utilizes radiotracers like [F]fluorodeoxyglucose (FDG) to measure brain activity in health and disease. Performing behavioral tasks between the FDG injection and the PET scan allows the FDG signal to reflect task-related brain networks. Building on this principle, we introduce an approach called behavioral task-associated PET (beta-PET) consisting of two scans: the first after a mouse is familiarized with a conditioning chamber, and the second upon recall of contextual threat.
View Article and Find Full Text PDFAssessing the metabolism of the olfactory circuit by use of F-FDG PET-CT imaging in patients suspected of suffering from Alzheimer's disease or frontotemporal dementia.
Alzheimers Res Ther
October 2024
Department of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 EZ, The Netherlands.
Purpose: The loss of olfactory function is known to occur in patients suffering from (behavioral variant) frontotemporal dementia ((bv)FTD) and Alzheimer's disease (AD), although different pathophysiological mechanisms underpin this clinical symptom in both disorders. This study assessed whether brain metabolism of the olfactory circuit as assessed by positron emission tomography (PET) imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose ([F]-FDG) can distinguish these entities in different subsets of patients.
Methods: Patients presenting with cognitive decline were included from a prospectively kept database: (1) bvFTD patients, (2) AD patients and (3) patients with logopenic primary progressive aphasia (PPA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!